Want to see STXS full AI Analyst Report?
STXS Stock Chart & Stats
$1.45
$0.00(0.00%)
At close: 4:00 PM EDT
$1.45
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.91 - $2.98
Previous Close$1.33
Volume443.78K
Average Volume (3M)552.54K
Market Cap
$91.18M
Enterprise Value$171.97M
Total Cash (Recent Filing)$10.49M
Total Debt (Recent Filing)$5.17M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding100,202,180
10 Day Avg. Volume604,252
30 Day Avg. Volume552,541
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)11.17
Price to Sales (P/S)6.46
P/FCF Ratio-15.18
Enterprise Value/Market Cap1.89
Enterprise Value/Revenue5.72
Enterprise Value/Gross Profit10.29
Enterprise Value/Ebitda-8.29
Forecast
1Y Price Target
$3.00Price Target Upside106.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$34.33M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue GrowthRecurring revenue growth increases the share of business tied to procedure volumes, disposables, and services rather than one-time system deliveries. If catheter manufacturing catches up with demand, this mix can improve revenue visibility and support more durable gross-margin expansion.
Product And Regulatory ExpansionMultiple cleared and launched products broaden Stereotaxis’s addressable clinical workflows and create additional adoption pathways within hospitals. Initial orders, daily clinical use, and planned GenesisX installations provide tangible commercial validation beyond product development alone.
Validated Installed BaseA substantial treatment history and hospital footprint support clinical credibility with prospective customers and physicians. This installed base can also provide a foundation for recurring catheter, software, and service revenue as utilization expands and the product ecosystem develops.
Bears Say
Persistent Losses And Cash BurnSustained operating and free-cash-flow losses show that the business is not yet self-funding despite its commercial initiatives. Continued burn could require additional financing before the targeted H1 2027 cash-flow breakeven, increasing dilution and execution risk.
Catheter Supply ConstraintsDemand that cannot be fulfilled delays revenue conversion, procedure growth, and customer adoption of the catheter platform. Until manufacturing ramps and redundancy is established, supply limitations may prevent recurring revenue momentum from fully translating into operating leverage.
Weak System EconomicsVolatile system deliveries create uneven capital-equipment revenue, while low manufacturing volumes depress system margins. This combination makes near-term results dependent on individual installations and limits the company’s ability to absorb operating expenses through profitable scale.
Stereotaxis News
STXS FAQ
What was Stereotaxis’s price range in the past 12 months?
Stereotaxis lowest stock price was $0.91 and its highest was $2.98 in the past 12 months.
What is Stereotaxis’s market cap?
Stereotaxis’s market cap is $91.18M.
When is Stereotaxis’s upcoming earnings report date?
Stereotaxis’s upcoming earnings report date is Nov 10, 2026 which is in 11 days.
How were Stereotaxis’s earnings last quarter?
Stereotaxis released its earnings results on Aug 11, 2026. The company reported -$0.05 earnings per share for the quarter.
Is Stereotaxis overvalued?
According to Wall Street analysts Stereotaxis’s price is currently Undervalued.
Does Stereotaxis pay dividends?
Stereotaxis does not currently pay dividends.
What is Stereotaxis’s EPS estimate?
Stereotaxis’s EPS estimate is -0.05.
How many shares outstanding does Stereotaxis have?
Stereotaxis has 100,202,180 shares outstanding.
What happened to Stereotaxis’s price movement after its last earnings report?
Stereotaxis reported an EPS of -$0.05 in its last earnings report. Following the earnings report the stock price went down -4.11%.
Which hedge fund is a major shareholder of Stereotaxis?
Currently, no hedge funds are holding shares in STXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stereotaxis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.00 (106.90% Upside)
$3.00 (106.90% Upside)
Blogger Sentiment
Neutral
STXS Sentiment 67%
Sector Average 65%
Sector Average 65%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.83%
12-Months-Change
Fundamentals
Return on Equity
-132.62%
Trailing 12-Months
Asset Growth
35.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Stereotaxis
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
STXS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call contained multiple material positive operational and commercial milestones (FDA clearances, product launches, strong sequential and year‑over‑year growth in robotically navigated catheter revenue, Synchrony early sales, GenesisX installs and OEM compatibility progress, strategic Robocath acquisition) that point to an improving growth trajectory and a clear path to higher recurring revenue and margin expansion. Offsetting these positives are near‑term execution challenges: supply constraints for MAGiC catheters limiting sales, a YoY decline in system revenue driven by a missed system delivery, depressed system margins due to low volumes, ongoing operating losses and negative free cash flow, and transition‑related procedure pressure. Management provided concrete guidance and reiterated a plan to reach cash‑flow profitability in H1 2027, relying on manufacturing ramp and modest capital sales. Overall, the call indicates constructive commercial inflection and credible progress toward profitability, but with meaningful near‑term operational and financial risks that must be managed.View all STXS earnings summariesSTXS Stock 12 Month Forecast
Average Price Target
$3.00
▲(106.90% Upside)
Technical Analysis
Atricure
―
Lemaitre Vascular
―
Merit Medical Systems
―
Staar Surgical
―
Milestone Scientific
―
Ownership Overview
20.29% Insiders
6.37% Mutual Funds
1.96% Other Institutional Investors
65.19% Public Companies and
Individual Investors